EYPT - Rasio utang marang kapitalisasi buku EyePoint Pharmaceuticals Inc

Logo grafis EyePoint Pharmaceuticals Inc (EYPT)

EyePoint Pharmaceuticals (EYPT) is implementing innovative implants that reduce the number of injections, accelerating the expansion of its product line. The development of sustained-release drug delivery systems relies on close collaboration with scientific centers. The stock price trend on the GURU.Markets platform, which stands at 0.12, depends on the outcomes of the final DURAVYU tests, the safety profile, and the company's liquidity reserve.

EYPT (EyePoint Corp) riwayat Utang marang nilai buku saka 04.07.2022 nganti 27.10.2026

Rincian metrik lan analitis perusahaan EyePoint Pharmaceuticals Inc (EYPT)

- rega lan prakiraan konsensus rega:
Rega saham EyePoint Pharmaceuticals|EYPT - Prakiraan konsensus analis
- data kapitalisasi pasar:
Nilai pasar EyePoint Corp|EYPT - Nilai Dipunlarasaken Utang lan Kas
- data kapitalisasi buku:
Aset Bersih saben Siji Saham EyePoint Pharmaceuticals|EYPT - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku eyepointpharma.com|EYPT - Total Aset Perusahaan
- data utang lan likuiditas:
Rasio Total Utang marang Ekuitas EyePoint Pharmaceuticals|EYPT - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal EyePoint Pharma|EYPT - Utang kumulatif perusahaan|Utang marang nilai buku EyePoint Corp
Analisis kabeh metrik perusahaan:EyePoint Pharmaceuticals - EYPT
Barang utama EyePoint Pharmaceuticals Inc

This ratio measures the business's dependence on borrowed funds relative to equity, determining financial stability and default risk. For EyePoint Pharmaceuticals (EYPT), which invests in costly clinical trials for microimplants, the debt-to-book capitalization ratio on GURU.Markets reflects the balance between leverage and the potential for future excess profits from proprietary drug delivery technologies.

Pesaing EyePoint Pharmaceuticals

Utang-utang marang kapitalisasi buku ALC (Alcon Inc.)|bausch.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Glaukos (GKOS)|APLS: Rasio utang marang aset resik|BLTE (Belite Bio) - Rasio utang marang kapitalisasi buku|Ocular Pharma (OCUL) - Utang marang nilai buku|HROW (Harrow, Inc.) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku viridiantherapeutics.com (VRDN)|LENZ Therapeutics (LENZ) - Utang marang nilai buku|Rasio utang marang aset resik Oaktree Specialty Lending (OCS)|KOD: Utang-utang marang kapitalisasi buku|ALDX - Utang-utang marang nilai buku|KALA (Kala Pharmaceuticals) - Utang marang nilai buku|IRD - Utang-utang marang nilai buku|Utang-utang marang kapitalisasi buku OKYO|ADVM (Adverum Biotechnologies, Inc.) - Utang-utang marang nilai buku|OTLK: Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik Clearside Corp|NovaBay Pharmaceuticals - Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku kiorapharma.com KPRX|ALIM: Utang marang nilai buku|Utang-utang marang nilai buku Eyenovia Inc. EYEN|GHSI (Guardion Health Sciences Inc.) - Utang-utang marang kapitalisasi buku|OCUP: Utang-utang marang nilai buku|Rasio utang marang kapitalisasi buku Opthea Limited (OPT)